StreetInsider.com News Articles

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Nyxoah SA (NYXH) Reiterated at Hold by Stifel: Will Breakeven in '2028 if Not Sooner'

Thu, 09 Jul 2026 07:09:15 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $3.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "We addressed Nyxoah’s 2Q26 preannouncement last night, so we focus on the (limited) incremental takeaways from the Investor Day. The most helpful color was likely specific to the path for Inspire Medical to obtain a specific HGNS code starting in 2028, rather than any incremental information that would alter our cautious stance on Nyxoah.In short, we view the company’s €150MM breakeven revenue aspiration (for 2028, if not sooner), 80% GM (from 61% LTM), and only measured increases in opex as best

Nyxoah SA (NYXH) Reiterated at Hold by Stifel as More Share Dilution Expected

Wed, 08 Jul 2026 07:38:03 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $3.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "While 2026 Street estimates most likely remain unchanged following 2Q26 top-line results, they are not moving higher, and Nyxoah’s march toward cash flow breakeven remains at least a couple of years away, in our opinion. Our estimates already appear aggressive (see bullet below), with our 2028E reflecting Genio capturing 40% of the incremental HGNS market. Management is assuming an even steeper ramp.Recall, our May 2026 downgrade made the case that $200MM+ in additional capital will be needed for Nyxoah to reach

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html

Nyxoah SA (NYXH) PT Lowered to $3 at Stifel post SLEEP Conference

Wed, 17 Jun 2026 07:08:40 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $3.00 (from $5.00) while maintaining a Hold rating.

The analyst commented, "Yesterday, we attended the SLEEP conference in Baltimore, MD and provide takeaways below.Inspire Medical: While more work needs to be done updating/educating facilities around prior reimbursement changes, we believe the worst is behind Inspire, and green shoots are starting to emerge. We take up our prior below Street 2Q26 revenue estimate and now reflect a -11% y/y decline (in-line with Street; 2026E moves modestly higher). We reiterate our stance that the stock is cheap, and although

Nyxoah SA (NYXH) PT Lowered to $3 at Stifel post SLEEP Conference

Wed, 17 Jun 2026 07:08:40 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $3.00 (from $5.00) while maintaining a Hold rating.

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

Nyxoah SA (Euronext Brussels/NASDAQ: NYXH) completed a $95 million equity financing and expects to receive a $15 million second tranche from its European Investment Bank loan by the end of June 2026, according to a press release statement.

The medical technology company develops treatments for obstructive sleep apnea and plans to use the $110 million in total capital to accelerate commercialization of its Genio system in the United States. The company currently has 40 sales representatives in place under U.S.-based commercial leadership.

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our